Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

APTO has been the subject of a number of other research reports. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $130.00.

Aptose Biosciences Trading Up 6.0 %

Shares of APTO opened at $3.70 on Thursday. Aptose Biosciences has a 12-month low of $2.39 and a 12-month high of $51.61. The company has a market cap of $7.92 million, a PE ratio of -1.25 and a beta of 1.14. The stock has a 50-day moving average price of $4.63 and a 200-day moving average price of $7.59.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 703,384 shares of the biotechnology company’s stock after acquiring an additional 301,634 shares during the period. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.